A patient with standard-risk newly diagnosed multiple myeloma is not undergoing up-front autologous stem-cell transplantation. After induction with a proteasome inhibitor-lenalidomide combination, the care team is considering indefinite-duration versus fixed-duration lenalidomide maintenance.
What does the evidence in this abstract support for this patient population?
